Report cover image

Osteoarthritic Pain Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146996

Description

Approximately 240 million people worldwide have symptomatic osteoarthritis, including 18% of women and 10% of men aged 60 years and older. Osteoarthritic pain is considered a common symptom of osteoarthritis, with localized pain experienced in specific joints like the knees, hips, hands, or spine. Management of osteoarthritic pain requires a combination of treatments including lifestyle modifications, pharmacological options, and surgery in severe cases. The growing adoption of non-invasive treatments and the rising focus on biologics and novel therapeutics are likely to boost the growth of the drug pipeline in the near future.

Report Coverage

The Osteoarthritic Pain Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into osteoarthritic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteoarthritic pain. The osteoarthritic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteoarthritic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with osteoarthritic pain treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteoarthritic pain.

Osteoarthritic Pain Drug Pipeline Outlook

Osteoarthritic pain is a common symptom of osteoarthritis, which develops gradually and often varies in intensity depending on factors such as joint overuse, inflammation, and structural changes in the joint. The pain is usually confined to specific joints (knees, hips, hands, and spine), but may radiate to other areas. Osteoarthritic pain is commonly activity-induced with movements worsening the discomfort experienced by the patients.

Osteoarthritic pain therapeutics include analgesics (acetaminophen and NSAIDs), intra-articular injections (corticosteroids and hyaluronic acid), and topical agents, among others. Osteoarthritic pain emerging drugs like nerve growth factor (NGF) inhibitors target pain pathways with high specificity. Further, the increasing investment in research and development and the rising focus on disease-modifying drugs are anticipated to support the drug pipeline expansion in the coming years.

Osteoarthritic Pain Epidemiology

Osteoarthritis is a degenerative joint condition that causes symptoms of pain, stiffness, and swelling. In the United States, osteoarthritis affects 32.5 million adults, with the prevalence increasing significantly with age.

As per the Centers for Disease Control and Prevention (CDC), 1 out 5 adults in the United States are living with some type of arthritis, with osteoarthritis being the most the form of the disease.

Osteoarthritic Pain – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of osteoarthritic pain drug candidates based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Biologics
  • Gene Therapy
  • Peptides
  • Synthetic Hormones
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
Osteoarthritic Pain – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of osteoarthritic pain drugs undergoing clinical development.

Osteoarthritic Pain – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under osteoarthritic pain pipeline analysis include small molecules, biologics, gene therapy, peptides, synthetic hormones, and others. The osteoarthritic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteoarthritic Pain.

Osteoarthritic Pain Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the osteoarthritic pain drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed osteoarthritic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in osteoarthritic pain clinical trials:
  • Kolon TissueGene, Inc.
  • Grünenthal GmbH
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd.
  • Saol Therapeutics Inc
  • Curonix LLC
Osteoarthritic Pain – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: RTX-GRT7039

Sponsored by Grünenthal GmbH, the objective of this randomized clinical trial is to investigate the efficacy and safety of the osteoarthritic pain drug candidate RTX-GRT7039 in patients experiencing moderate to severe pain associated with knee osteoarthritis. The study is under Phase III clinical development and has an estimated 930 participants.

Drug: SL-1002

Saol Therapeutics Inc. is conducting a Phase II study aimed at examining the efficacy and safety of the investigational injectable drug SL-1002 for osteoarthritic knee pain. The clinical trial has enrolled about 132 subjects and has a study period of up to 168 days.

Reasons To Buy This Report

The Osteoarthritic Pain Drug Report provides a strategic overview of the latest and future landscape of treatments for osteoarthritic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within osteoarthritic pain pipeline insights.

Key Questions Answered in the Osteoarthritic Pain – Pipeline Insight Report
  • What is the current landscape of osteoarthritic pain disease pipeline drugs?
  • Which companies/institutions are developing osteoarthritic pain disease emerging drugs?
  • How many phase II drugs are currently present in osteoarthritic pain disease pipeline drugs?
  • Which company is leading the osteoarthritic pain disease pipeline development activities?
  • What is the current osteoarthritic pain disease therapeutic assessment?
  • What are the opportunities and challenges present in the osteoarthritic pain disease drug pipeline landscape?
  • What is the efficacy and safety profile of osteoarthritic pain disease pipeline drugs?
  • Which companies/institutions are involved in osteoarthritic pain disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in osteoarthritic pain disease?
Related Reports

Osteoarthritis Therapeutics Market

Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Osteoarthritic Pain
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Osteoarthritic Pain
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Osteoarthritic Pain: Epidemiology Snapshot
5.1 Osteoarthritic Pain Incidence by Key Markets
5.2 Osteoarthritic Pain – Patients Seeking Treatment in Key Markets
6 Osteoarthritic Pain: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Osteoarthritic Pain: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Osteoarthritic Pain, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Osteoarthritic Pain Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Osteoarthritic Pain Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: RTX-GRT7039
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Biological: TG-C
10.2.3 Other Drugs
11 Osteoarthritic Pain Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Cannabidiol (CBD)
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: SL-1002
11.2.3 Other Drugs
12 Osteoarthritic Pain Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: ASKC200
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: Autologous Adipose Derived Mesenchymal Stromal Cells
12.2.3 Other Drugs
13 Osteoarthritic Pain Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Osteoarthritic Pain, Key Drug Pipeline Companies
14.1 Kolon TissueGene, Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Grünenthal GmbH
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Saol Therapeutics Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Curonix LLC
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us